Celestamine | 62682-62-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Celestamine
• 英文别名: (Z)-but-2-enedioic acid;(3S)-3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine;(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• CAS: 62682-62-6
• 化学式: C42H52ClFN2O9
• 分子量: 783.3
• InChiKey: AKMWMFINHABZNA-ZVOBBGBPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.43
• 重原子数：
  55
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  186
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• ORAL PHARMACEUTICAL PREPARATION FOR COLON-SPECIFIC DELIVERY
  申请人：TEIKOKU SEIYAKU CO., LTD.

  公开号：EP2143424A1

  公开（公告）日：2010-01-13

  The present invention relates to an oral pharmaceutical preparation having an excellent capability of delivering a drug to colon, more specifically an oral pharmaceutical preparation for delivering a drug to colon and comprising a core comprising at least a pharmaceutically acceptable vehicle, an inner layer covering said core and comprising said drug, an intermediate layer covering said inner layer and comprising a cationic polymer soluble or swellable at a pH of not more than 6.6, and an outer layer covering said intermediate layer and comprising an anionic polymer soluble at a pH of not less than 7.0.

  本发明涉及一种口服药物制剂，该制剂具有向结肠输送药物的优异能力，更具体地说，是一种向结肠输送药物的口服药物制剂，包括至少由药学上可接受的载体组成的核心；覆盖所述核心并包含所述药物的内层；覆盖所述内层并包含可在 pH 值不高于 6.6 的条件下溶解或膨胀的阳离子聚合物的中间层；以及覆盖所述中间层并包含可在 pH 值不低于 7.0 的条件下溶解的阴离子聚合物的外层。
• Compositions for colonic delivery of drugs
  申请人：PATHEON SOFTGELS INC

  公开号：US10182993B2

  公开（公告）日：2019-01-22

  Described herein are controlled release oral pharmaceutical compositions for delivering active pharmaceutical ingredients to the colon and methods for making the same. In particular, an oral pharmaceutical composition comprising a soft capsule and a controlled release matrix for delivering active pharmaceutical ingredients to the colon are described.

  本文描述了向结肠输送活性药物成分的控释口服药物组合物及其制造方法。特别是描述了一种口服药物组合物，它由软胶囊和控释基质组成，用于向结肠输送活性药物成分。
• OPIOID ANTAGONIST FORMULATIONS
  申请人：Purdue Pharma L.P.

  公开号：EP3086789A1

  公开（公告）日：2016-11-02
• Opioid Antagonist Formulations
  申请人：PURDUE PHARMA L.P.

  公开号：US20160243107A1

  公开（公告）日：2016-08-25

  In certain embodiments, the present invention is directed to a solid controlled-release dosage form comprising a core comprising a core portion of an opioid antagonist and a shell encasing the core and comprising a shell portion of the opioid antagonist, wherein the release profile of the core portion of opioid antagonist is different than the release profile of the shell portion of opioid antagonist.
• COMPOSITIONS FOR COLONIC DELIVERY OF DRUGS
  申请人：BANNER LIFE SCIENCES LLC

  公开号：US20160287525A1

  公开（公告）日：2016-10-06

  Described herein are controlled release oral pharmaceutical compositions for delivering active pharmaceutical ingredients to the colon and methods for making the same. In particular, an oral pharmaceutical composition comprising a soft capsule and a controlled release matrix for delivering active pharmaceutical ingredients to the colon are described.